Trexquant Investment LP Sells 87,781 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

Trexquant Investment LP trimmed its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOKFree Report) by 68.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 39,800 shares of the company’s stock after selling 87,781 shares during the quarter. Trexquant Investment LP owned about 0.09% of Stoke Therapeutics worth $209,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Lynx1 Capital Management LP bought a new position in Stoke Therapeutics during the third quarter worth about $6,738,000. GSA Capital Partners LLP increased its position in Stoke Therapeutics by 514.7% during the third quarter. GSA Capital Partners LLP now owns 348,069 shares of the company’s stock worth $1,371,000 after acquiring an additional 291,443 shares during the period. Bank of New York Mellon Corp increased its position in Stoke Therapeutics by 2.8% during the third quarter. Bank of New York Mellon Corp now owns 107,254 shares of the company’s stock worth $423,000 after acquiring an additional 2,926 shares during the period. Los Angeles Capital Management LLC increased its position in Stoke Therapeutics by 30.4% during the fourth quarter. Los Angeles Capital Management LLC now owns 62,257 shares of the company’s stock worth $327,000 after acquiring an additional 14,510 shares during the period. Finally, Public Employees Retirement System of Ohio bought a new position in Stoke Therapeutics during the third quarter worth about $64,000.

Insiders Place Their Bets

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 3,600,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the sale, the insider now directly owns 10,843,681 shares of the company’s stock, valued at approximately $125,786,699.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 5,126 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $13.20, for a total transaction of $67,663.20. Following the sale, the general counsel now directly owns 2,598 shares of the company’s stock, valued at approximately $34,293.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Skorpios Trust sold 3,600,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the sale, the insider now directly owns 10,843,681 shares in the company, valued at $125,786,699.60. The disclosure for this sale can be found here. Insiders have sold 3,622,741 shares of company stock valued at $41,935,115 in the last ninety days. 11.30% of the stock is currently owned by insiders.

Stoke Therapeutics Trading Up 3.2 %

Shares of Stoke Therapeutics stock opened at $16.41 on Thursday. The firm has a market capitalization of $855.29 million, a PE ratio of -6.81 and a beta of 0.88. The firm’s 50 day moving average is $13.05 and its 200 day moving average is $8.13. Stoke Therapeutics, Inc. has a 1 year low of $3.35 and a 1 year high of $16.69.

Stoke Therapeutics (NASDAQ:STOKGet Free Report) last announced its quarterly earnings results on Monday, May 6th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.03. The company had revenue of $4.22 million for the quarter, compared to the consensus estimate of $3.33 million. As a group, research analysts anticipate that Stoke Therapeutics, Inc. will post -2.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research report on Thursday, April 4th. Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Monday, May 6th. JPMorgan Chase & Co. boosted their target price on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a research report on Tuesday, March 26th. TD Cowen upgraded shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 26th. Finally, Wedbush boosted their target price on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the company an “outperform” rating in a research report on Tuesday, March 26th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Stoke Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $20.57.

View Our Latest Research Report on STOK

Stoke Therapeutics Profile

(Free Report)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

Featured Stories

Want to see what other hedge funds are holding STOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stoke Therapeutics, Inc. (NASDAQ:STOKFree Report).

Institutional Ownership by Quarter for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.